Market Access Views & Analysis

Views & Analysis

How does HTA for orphan drugs differ across Europe?

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe.

Views & Analysis

Preparing for an influx of cell and gene therapy approvals

Cell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has ever seen.

Views & Analysis

London, January 26, 2020. People wearing a face masks to protecting themself because of epidemic in China. Selective Focus. Concept of coronavirus quarantine. MERS-Cov, middle East respiratory syndrome coronavirus, Novel coronavirus 2019-nCoV.

Coronavirus pharma news roundup – 31/07/20

Vaccines, AI-driven drug discovery and llamas all hit the headlines this week as the search for a way to end the COVID-19 pandemic continues.

Views & Analysis

Country focus: Iraq’s pharma industry sees upward trajectory

After decades of turmoil, Iraq’s healthcare sector is growing fast – but the country still holds some unique challenges for companies looking to enter its market.

Views & Analysis

Coronavirus pharma news roundup – 24/07/20

With coronavirus vaccine trials finally showing positive results, analysts are starting to wonder what access challenges might lie ahead.

Views & Analysis

MSD’s David Peacock on moving UK healthcare forward

David Peacock has worked across the world for MSD and other companies, and has now taken the helm of MSD’s UK & Ireland operations.

How does HTA for orphan drugs differ across Europe?

Preparing for an influx of cell and gene therapy approvals

Coronavirus pharma news roundup – 31/07/20

Country focus: Iraq’s pharma industry sees upward trajectory

Coronavirus pharma news roundup – 24/07/20

MSD’s David Peacock on moving UK healthcare forward

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks